Advances in cancer research最新文献_第6页

Plasticity in cell adhesion during tumor progression. 肿瘤进展过程中细胞粘附的可塑性。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-23 DOI: 10.1016/bs.acr.2025.06.001

Arka Saha, Avri Ben-Ze'ev

引用次数: 0

Liquid biopsy in early detection and monitoring of CNS metastases. 液体活检在早期发现和监测中枢神经系统转移中的作用。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-21 DOI: 10.1016/bs.acr.2025.04.007

Natasha Hongsermeier-Graves, Mohammed Hasen, Noah Yaffe, Andrew Ajisebutu, Rachna Malani

引用次数: 0

Craniopharyngioma. 颅咽管瘤。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-10-20 DOI: 10.1016/bs.acr.2025.09.005

Eric Montgomery, Siddhartha Mitra, Cassie Kline, Todd C Hankinson

{"title":"Craniopharyngioma.","authors":"Eric Montgomery, Siddhartha Mitra, Cassie Kline, Todd C Hankinson","doi":"10.1016/bs.acr.2025.09.005","DOIUrl":"10.1016/bs.acr.2025.09.005","url":null,"abstract":"Introduction Adamantinomatous craniopharyngioma (ACP) is a significant source of morbidity in the pediatric brain tumor population. It predominantly arises from the parasellar space. The tumors proximity to key vital structures often makes gross total surgical resection challenging and sometimes clinically inadvisable. Compounding the problem, adjunct therapies are not yet capable of providing a definitive cure. Recent preclinical research has made significant progress towards elucidating the mutagenic drivers of ACP, however much work remains to translate this into safe and effective treatments. Content Overview and Key Takeaways In the following chapter, we discuss the most up-to-date understanding of ACP biology and management. ACP is a histologically low grade tumor characterized by a mutation involving the beta-catenin protein, resulting in pathologic stability of the protein that impairs cell death or apoptosis. A subpopulation of tumor cells then enter a transcriptomic state characterized by cellular oncogenic senescence. It is unclear how this state leads to feed forward loops resulting in tumorigenesis. Despite its benign nature, the consistent anatomic origin of ACP in the sellar/suprasellar space, often abutting or involving the hypothalamus, the infundibulum, and the optic chiasm, contributes to multiple long-term complications such as endocrinopathies, obesity, vision loss, and obstructive hydrocephalus. Surgically, the current trend is towards conservative approaches with the goal of maximal safe resection without perturbing the hypothalamus. Adjunct radiotherapy is standard in cases of residual or recurrent disease. Close coordination with endocrinology colleagues is vital to appropriately care for these patients as they often suffer from lifelong endocrinopathies that remain a significant source of burden in this population.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"167 ","pages":"243-277"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the diagnosis and management of Choroid Plexus tumors. 脉络膜丛肿瘤的诊断和治疗综述。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-09-20 DOI: 10.1016/bs.acr.2025.08.008

Diana S Osorio, Maxim Yankelevich, Lucie Lafay-Cousin, Wafik Zaky

{"title":"An overview of the diagnosis and management of Choroid Plexus tumors.","authors":"Diana S Osorio, Maxim Yankelevich, Lucie Lafay-Cousin, Wafik Zaky","doi":"10.1016/bs.acr.2025.08.008","DOIUrl":"10.1016/bs.acr.2025.08.008","url":null,"abstract":"Choroid Plexus Tumors (CPT) are rare (2-4% of all pediatric CNS tumors), predominantly early childhood brain neoplasms. Due to their rarity and the lack of prospective clinical trials, evidence-based treatment guidelines remain limited. This review provides a comprehensive summary of the current knowledge.nnCPTs span a spectrum from mature Choroid Plexus Papillomas (CPP) to malignant Choroid Plexus Carcinomas (CPC), with Atypical Choroid Plexus Papillomas (aCPP) in between. A significant proportion of CPCs are driven by either somatic or germline TP53 mutations (Li-Fraumeni syndrome); however, other molecular drivers of CPT tumorigenesis remain poorly understood. CPTs exhibit distinct DNA methylation profiles, allowing for classification into clinically relevant subgroups. These tumors also display a chromosomal instability phenotype, characterized by multiple copy number alterations. nnAdvances in molecular profiling have revealed that TP53-mutated CPCs have significantly worse outcomes. Both retrospective and limited prospective data have shown 5-year event-free survival rates of 0-25% for TP53-mutant CPCs versus 70-80% for TP53-wild-type cases. The extent of surgical resection remains another established prognostic factor, while data on the roles of radiation therapy (RT) and myeloablative chemotherapy with stem cell rescue are still evolving. Preliminary evidence suggests that TP53-mutant patients may be getting less benefit from RT, but greater benefit from myeloablative chemotherapy approach with avoidance of RT.nn The emerging insights into CPC biology and long-term outcomes can direct the design of future clinical trials. A new international prospective study led by the Pediatric Neuro-Oncology Consortium is in development, with the goal to stratify patients by molecular subtype to receive different therapy based on individual molecular profiles and patient age.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"167 ","pages":"103-139"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Michael addition drugs and cancer. 迈克尔增加了毒品和癌症。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-24 DOI: 10.1016/bs.acr.2025.06.004

Kenneth D Tew, Danyelle M Townsend, Leilei Zhang, Xuhong Zhang, Zhiwei Ye, Jie Zhang

{"title":"Michael addition drugs and cancer.","authors":"Kenneth D Tew, Danyelle M Townsend, Leilei Zhang, Xuhong Zhang, Zhiwei Ye, Jie Zhang","doi":"10.1016/bs.acr.2025.06.004","DOIUrl":"10.1016/bs.acr.2025.06.004","url":null,"abstract":"Some of the earliest anticancer drugs were alkylating agents, capable of covalently modifying critical cellular nucleophiles in proteins and nucleic acids. For many years, adapting another type of covalent reaction, Michael addition reactions, which involve the nucleophilic attack of a carbon nucleophile on an α,β-unsaturated carbonyl compound, have been explored in designing covalent inhibitors that selectively target cancer-related biomolecules. Numerous natural products demonstrate Michael addition properties, contributing to their bioactivity in antioxidant, anti-inflammatory and anticancer mechanisms. These compounds often interact with cellular nucleophiles, modulating redox signaling, enzyme catalysis, and stress response pathways. In the context of cancer treatments, several FDA-approved drugs, including proteostatic, EGFR and Ras inhibitors, employ Michael addition chemistry to achieve irreversible inhibition of cancer-related targets. The review emphasizes the challenges associated with these drugs, including off-target effects, toxicity, and drug resistance, but highlights some advances in medicinal chemistry that have improved selectivity and therapeutic efficacy. There are emerging covalent inhibitors that leverage Michael addition to enhance cancer treatment, underscoring the ongoing efforts to refine these compounds for clinical translation. Overall, this review examines the mechanisms, applications, and therapeutic potentials of Michael addition drugs in oncology, alongside relevant literature, and clinical findings.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"168 ","pages":"196-220"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface. 前言。

Advances in cancer research Pub Date : 2025-01-01 DOI: 10.1016/S0065-230X(25)00042-9

Mariza Daras, David D Limbrick, Paul B Fisher

引用次数: 0

Preface. 前言。

Advances in cancer research Pub Date : 2025-01-01 DOI: 10.1016/S0065-230X(25)00070-3

Mohamed S Abdelbaki, Paul B Fisher, David D Limbrick

引用次数: 0

Molecular drivers in primary brain tumor formation. 原发性脑肿瘤形成的分子驱动因素。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-25 DOI: 10.1016/bs.acr.2025.04.006

Hope T Richard

引用次数: 0

Molecular drivers in CNS metastatic disease. 中枢神经系统转移性疾病的分子驱动因素。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-30 DOI: 10.1016/bs.acr.2025.04.004

Hannah Kim, Sofia Chernet, Priya Kumthekar, Akanksha Sharma

引用次数: 0

In search of a targetable immune profile for acute myeloid leukemia. 寻找急性髓性白血病的可靶向免疫谱。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-07-12 DOI: 10.1016/bs.acr.2025.06.005

Gurnit Kaur, Negar Ghaffari, Nagesh Kalakonda, William Grey, Vanessa Marensi

引用次数: 0